Blog
RSS FeedPosted by Michael Wonder on 07 Nov 2019
Little consistency in evidence cited by commercial plans for specialty drug coverage
5 November 2019 - Recently published research indicates wide variation in the evidence that US commercial health plans reported reviewing ...
Posted by Michael Wonder on 02 Oct 2019
Advancing patient engagement
2 October 2019 - It’s widely accepted that seeking patient input into their health and care improves outcomes for them and ...
Posted by Michael Wonder on 02 Oct 2019
How to ensure that novel analytic methods are fit for decision-making
2 October 2019 - The past decade has seen the increased generation and availability of new data sources such as ...
Posted by Michael Wonder on 23 Sep 2019
Health‐related quality of life in oncology drug reimbursement submissions in Canada: a review of submissions to the pan‐Canadian Oncology Drug Review
23 September 2019 - In Canada, CADTH evaluates and makes recommendations for the reimbursement of cancer drugs. One component of ...
Posted by Michael Wonder on 12 Sep 2019
When are RCTs required for breakthrough drugs, HDEs? JAMA study investigates
11 September 2019 - A new study in JAMA Network Open finds that drugs and medical devices approved by the ...
Posted by Michael Wonder on 11 Sep 2019
The use of validated and non-validated surrogate endpoints in two EMA expedited approval pathways: A cross-sectional study of products authorised 2011–2018
10 September 2019 - In situations of unmet medical need or in the interests of public health, expedited approval pathways, ...
Posted by Michael Wonder on 09 Sep 2019
As value assessment frameworks evolve, are they finally ready for prime time?
9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...
Posted by Michael Wonder on 28 Aug 2019
Patient Voice Aotearoa calls for PHARMAC reform
28 August 2019 - Patient Voice Aotearoa has launched a petition calling for the Minister of Health to initiate an ...
Posted by Michael Wonder on 27 Aug 2019
Incorporating affordability concerns within cost-effectiveness analysis for health technology assessment
27 August 2019 - New framework considers the scale, time profile, and uncertainty of budget impacts. ...
Posted by Michael Wonder on 27 Aug 2019
Pharmacists demand audit over Gliatilin’s insurance benefit
27 August 2019 - A pharmacists’ group demanded an audit against the Ministry of Health and Welfare and the Health ...
Posted by Michael Wonder on 26 Aug 2019
Developing real-world data and evidence to support regulatory decision-making
26 August 2019 - On 3 October, the FDA and the Duke-Margolis Center for Health Policy will hold a conference, ...
Posted by Michael Wonder on 21 Aug 2019
Former FDA Commissioners seek to expand use of RWE in regulatory, payment decisions
21 August 2019 - A new report from the Bipartisan Policy Center makes recommendations to expand the use of real-world ...
Posted by Michael Wonder on 21 Aug 2019
ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures
21 August 2019 - Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis ...
Posted by Michael Wonder on 18 Aug 2019
Lack of transparency hampers cancer drug debate
19 August 2019 - The current debate raging over cancer drug funding is emotional, and the different agenda of lobby ...
Posted by Michael Wonder on 15 Aug 2019
ICER's value framework and patient feedback: Q&A with Steve Pearson
15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...